<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Balloon Juice</provider_name><provider_url>https://balloon-juice.com</provider_url><author_name>David Anderson</author_name><author_url>https://balloon-juice.com/author/richard-mayhew/</author_url><title>Balloon Juice - Utilization management through hassle or guidelines</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="WZGhBg9Uon"&gt;&lt;a href="https://balloon-juice.com/2017/03/02/utilization-management-through-hassle-or-guidelines/"&gt;Utilization management through hassle or guidelines&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://balloon-juice.com/2017/03/02/utilization-management-through-hassle-or-guidelines/embed/#?secret=WZGhBg9Uon" width="600" height="338" title="&#x201C;Utilization management through hassle or guidelines&#x201D; &#x2014; Balloon Juice" data-secret="WZGhBg9Uon" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><description>The Alliance for Patient Access (a combination of drug industry advocacy group and physician advocacy group) released an interesting report early last week. It looked at the denial rates of PCSK9 inhibitors. This is a new class of anti-cholesterol drugs that are targeted at individuals with an unusual genotype and high cholesterol. The drugs are &hellip;</description><thumbnail_url>http://1yh21u3cjptv3xjder1dco9mx5s.wpengine.netdna-cdn.com/wp-content/uploads/2017/02/Screen-Shot-2017-02-21-at-10.07.45-AM.jpg</thumbnail_url></oembed>
